SCHEMBL25599540

SCHEMBL25599540

C=C1CC(C)CC(CC[C@H](NC(=O)c2ccc3ccc(Cl)cc3c2OCc2ccc(OC(F)(F)F)cc2)C(=O)O)C1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.36
SLC6A4 P31645 1/20 0.34
GPR132 Q9UNW8 1/20 0.34
CXCR2 P25025 1/20 0.33
TRPV1 Q8NER1 1/20 0.32
NHERF1 O14745 1/20 0.32
DHODH Q02127 1/20 0.32
CTNNB1 P35222 5/20 0.32
IDH1 O75874 2/20 0.32
CDH1 P12830 1/20 0.32
TCF4 P15884 1/20 0.32
TCF7 P36402 1/20 0.32
GCGR P47871 1/20 0.32
CYP3A4 P08684 1/20 0.31
UGCG Q16739 1/20 0.31
YAP1 P46937 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25599221 0.93 GPR132 (0.35) PTPN1GPR132CXCR2TRPV1YAP1
SCHEMBL25599537 0.92 CXCR2 (0.41) PTPN1SLC6A4GPR132CXCR2NHERF1
SCHEMBL25599046 0.91 CXCR2 (0.41) PTPN1GPR132CXCR2TRPV1YAP1
SCHEMBL25599487 0.89 GPR132 (0.34) PTPN1GPR132CXCR2TRPV1IDH1
SCHEMBL25601942 0.85 CXCR2 (0.39) PTPN1SLC6A4CXCR2CTNNB1CYP3A4
SCHEMBL25599106 0.84 CXCR2 (0.42) PTPN1GPR132CXCR2CTNNB1CYP3A4
SCHEMBL25599374 0.82 CXCR2 (0.51) PTPN1GPR132CXCR2CYP3A4UGCG
SCHEMBL25599284 0.82 CXCR2 (0.51) PTPN1GPR132CXCR2CYP3A4UGCG
SCHEMBL25599235 0.82 CXCR2 (0.40) PTPN1GPR132CXCR2YAP1
SCHEMBL25548900 0.81 PTPN1 (0.43) PTPN1GPR132CXCR2TRPV1NHERF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA PTPN1 1876/4885SLC6A4 1384/4885GPR132 750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.